Hemab Therapeutics Holdings, Inc.(COAG)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

COAG Hemab Therapeutics Holdings, Inc.

盘后交易 09-04 16:23:31 EDT

44.41

+0.04

+0.09%

盘后44.41

+0.000.00%

16:10 EDT

最高45.49	最低43.29	成交量30.20万
今开43.40	昨收44.37	日振幅4.96%
总市值20.74亿	流通市值7.44亿	总股本4,671万
成交额1,345万	换手率1.80%	流通股本1,675万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"COAG","market":"US","secType":"STK","nameCN":"Hemab Therapeutics Holdings, Inc.","latestPrice":44.41,"timestamp":1788552000000,"preClose":44.37,"halted":0,"volume":302045,"hourTrading":{"tag":"盘后","latestPrice":44.41,"preClose":44.41,"latestTime":"16:10 EDT","volume":1227,"amount":54491.06999999999,"timestamp":1788552604736,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.0009015100292990568,"floatShares":16750000,"shares":46705400,"eps":-1.782,"marketStatus":"盘后交易","change":0.04,"latestTime":"09-04 16:23:31 EDT","open":43.4,"high":45.4925,"low":43.29,"amount":13452666,"amplitude":0.049639,"askPrice":45.25,"askSize":44,"bidPrice":43.57,"bidSize":45,"shortable":3,"etf":0,"ttmEps":-1.782,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1788566400000},"marketStatusCode":4,"adr":0,"listingDate":1777608000000,"exchange":"NASDAQ","adjPreClose":44.37,"preHourTrading":{"tag":"盘前","latestPrice":45.03,"preClose":44.37,"latestTime":"04:54 EDT","volume":1,"amount":45.03,"timestamp":1788512071543,"change":0.66,"changeRate":0.014875,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":44.41,"preClose":44.41,"latestTime":"16:10 EDT","volume":1227,"amount":54491.06999999999,"timestamp":1788552604736,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.861679},"requestUrl":"/m/hq/s/COAG","defaultTab":"news","newsList":[{"id":"1183732399","title":"H.C. Wainwright 首次覆盖 Hemab Therapeutics，给予“买入”评级及40美元目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1183732399","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1183732399?lang=zh_cn&edition=full","pubTime":"2026-06-17 18:08","pubTimestamp":1781690902,"startTime":"0","endTime":"0","summary":"投资机构 H.C. Wainwright 近日启动了对 Hemab Therapeutics Holdings, Inc. 的研究覆盖，并给予了“买入”评级。该机构为这家生物技术公司设定了每股40美元的目标价格。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","COAG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630437375","title":"诺和诺德基金会参投的生物科技公司Hemab(COAG.US)拟赴美IPO，最高募资2.12亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2630437375","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2630437375?lang=zh_cn&edition=full","pubTime":"2026-04-28 16:00","pubTimestamp":1777363239,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，临床阶段生物科技公司Hemab Therapeutics Holdings Inc.正寻求在美国首次公开募股中最高融资2.12亿美元。此次生物科技公司IPO的背景是，投资者对减肥药物开发商Kailera Therapeutics Inc.给予了热烈反响——该公司于本月初上市，募资7.19亿美元，创下2021年以来该行业在美国最大的IPO记录。招股文件还显示，在本次发行前，RA Capital Management的关联实体与诺和诺德基金会分别持有Hemab 18%和15%的股份。截至2025年12月31日，公司持有现金及现金等价物共1.85亿美元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1435195.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1093756325.SGD","NVO","LU0154236417.USD","BK4581","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","BK4599","LU1093756168.USD","NVOH","BK4532","BK4585","COAG","NVOX","BK4588","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195572245","title":"Hemab Therapeutics Holdings Inc提交SEC文件：预计IPO股价区间为16-18美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1195572245","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195572245?lang=zh_cn&edition=full","pubTime":"2026-04-27 19:22","pubTimestamp":1777288965,"startTime":"0","endTime":"0","summary":"根据最新提交给美国证券交易委员会（SEC）的文件显示，生物制药公司Hemab Therapeutics Holdings Inc首次公开募股（IPO）的初步定价区间已确定为每股16美元至18美元。\n这一价格区间标志着该公司正式迈出登陆公开资本市场的关键一步。若按此区间上限计算，此次IPO有望为Hemab Therapeutics募集可观的资金，用于推进其创新疗法的研发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COAG"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hemab.com","stockEarnings":[{"period":"1week","weight":-0.1035},{"period":"1month","weight":-0.0462},{"period":"3month","weight":0.7538},{"period":"6month","weight":1.465},{"period":"ytd","weight":1.465}],"compareEarnings":[{"period":"1week","weight":0.0027},{"period":"1month","weight":0.0024},{"period":"3month","weight":0.0483},{"period":"6month","weight":0.1499},{"period":"1year","weight":0.2011},{"period":"ytd","weight":0.1338}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Hemab Therapeutics Holdings, Inc.于2026年2月12日根据特拉华州法律注册成立。Hemab Therapeutics是一家临床阶段的生物技术公司，致力于开发革新血液凝固障碍治疗的疗法，以帮助维持生命并增强人类的抵抗力。公司的使命是通过发现、开发和商业化创新疗法，为全球患有严重出血和血栓性疾病的患者打造领先的凝血领域公司。这些疾病包括格氏血小板无力症、VII因子缺乏症、血管性血友病以及其他可能造成终身沉重负担的异常出血性疾病。公司的主要候选药物sutacimig (HMB-001) 是一种双特异性抗体，目前正在进行一项针对格氏血小板无力症预防性治疗的I/II期临床试验和一项针对VII因子缺乏症预防性治疗的II期临床试验。","exchange":"NASDAQ","name":"Hemab Therapeutics Holdings, Inc.","nameEN":"Hemab Therapeutics Holdings, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Hemab Therapeutics Holdings, Inc.(COAG)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Hemab Therapeutics Holdings, Inc.(COAG)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Hemab Therapeutics Holdings, Inc.,COAG,Hemab Therapeutics Holdings, Inc.股票,Hemab Therapeutics Holdings, Inc.股票老虎,Hemab Therapeutics Holdings, Inc.股票老虎国际,Hemab Therapeutics Holdings, Inc.行情,Hemab Therapeutics Holdings, Inc.股票行情,Hemab Therapeutics Holdings, Inc.股价,Hemab Therapeutics Holdings, Inc.股市,Hemab Therapeutics Holdings, Inc.股票价格,Hemab Therapeutics Holdings, Inc.股票交易,Hemab Therapeutics Holdings, Inc.股票购买,Hemab Therapeutics Holdings, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Hemab Therapeutics Holdings, Inc.(COAG)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Hemab Therapeutics Holdings, Inc.(COAG)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}